Acute hypokalemia caused by rituximab in a patient with nephrotic syndrome
10.3760/cma.j.cn114015-20211011-01052
- VernacularTitle:利妥昔单抗致肾病综合征患者急性低钾血症
- Author:
Huiying CHEN
1
;
Daliang XU
;
Ying ZHU
Author Information
1. 安徽省儿童医院临床药学部，合肥 230022
- Publication Type:Journal Article
- Keywords:
Rituximab;
Hypokalemia;
Drug-related side effects and adverse reactions
- From:
Adverse Drug Reactions Journal
2022;24(7):378-380
- CountryChina
- Language:Chinese
-
Abstract:
A 17-year-old male patient received rituximab due to nephrotic syndrome. No obvious discomfort occurred during the first treatment (500 mg by intravenous infusion). After half a year, when the second treatment (300 mg by intravenous infusion) was given, the patient developed symptoms such as fatigue of limbs and inability to lift both lower limbs. Laboratory test showed blood potassium 2.37 mmol/L. Before treatment, the serum potassium was 4.16 mmol/l, and other laboratory test indicators were basically normal. Acute hypokalemia caused by rituximab was considered. Oral potassium chloride was given. On the 2nd day, the symptoms in the patient were relieved, the feeling of powerlessness disappeared, and the blood potassium was 3.06 mmol/L. On the 3rd day, the blood potassium was 4.34 mmol/L. the potassium supplement was stopped after 3 days of medication. The next day, the blood potassium was 4.70 mmol/l, and the patient′s limb weakness and discomfort symptoms disappeared. After that, the patient did not use rituximab again, and no hypokalemia recurred.
